Hormone Replacement Therapy: Restoring Your Balance
At a Glance
For FXPOI, hormone replacement therapy replaces missing estrogen, helps relieve symptoms and protect bone health, and usually continues until about age 50 or 51. If you have a uterus, progestogen protects its lining, and HRT does not prevent pregnancy.
When you are diagnosed with Fragile X-Associated Primary Ovarian Insufficiency (FXPOI), your body stops producing the levels of estrogen and progesterone it normally would. Hormone Replacement Therapy (HRT) is the standard of care to “replace” these missing hormones [1][2].
Unlike treatment for women who go through menopause at the typical age (around 51), HRT for POI is not just about treating symptoms like hot flashes. It is about protecting your long-term health, helping to reduce the consequences of early hypoestrogenism, specifically bone loss, by restoring hormone levels to what they would naturally be in your 20s or 30s [2][3]. However, while it is beneficial, it does not completely restore normal ovarian function or provide a proven absolute guarantee of cardiovascular protection.
Physiological Dosing: Why More is Often Needed
Because you are replacing hormones that your body should be making at this stage of life, the doses used for FXPOI are typically higher than those used for older women in menopause [4][3]. This is often called physiological replacement—aiming to match the hormone environment of a premenopausal woman.
While the exact regimen depends on your symptoms, bone response, bleeding, and comorbidities, common clinician-guided examples for effective replacement include:
- Transdermal Estrogen: 100 micrograms (0.1 mg) per day via a patch or gel [5].
- Oral Estrogen: 2 mg per day of 17β-estradiol [5].
These are examples, not universal required doses; there is no single universally required serum estradiol target.
Methods of Treatment
There are two main hormones involved in HRT: estrogen (to replace what the ovaries make) and progestogen (to protect the lining of the uterus).
1. Estrogen Delivery
- Transdermal (Patches or Gels): This is often the preferred route for FXPOI [6][7]. When estrogen is absorbed through the skin, it goes directly into the bloodstream, bypassing the liver. This method is associated with a lower risk of blood clots (venous thromboembolism or VTE) and has less impact on triglyceride levels compared to pills [8][9].
- Oral (Pills): Some women prefer the convenience of a daily pill. While effective, oral estrogen can slightly increase the risk of blood clots in some populations [8].
(Note: Low-dose vaginal estrogen may be considered for genitourinary symptoms, but it does not replace systemic estrogen for bone protection.)
2. Progestogen (If you have a uterus)
If you still have your uterus, taking estrogen alone can cause the lining of the uterus to thicken, which increases the risk of uterine cancer. To prevent this, an adequate, evidence-based dose and schedule of a progestogen (a synthetic or natural form of progesterone) must be added for endometrial protection [10][11].
- Cyclical Regimen: You take progesterone for about 12–14 days each month, which usually results in a predictable monthly bleed [12][13]. Irregular bleeding is common early in treatment.
- Continuous Regimen: You take a lower dose of progesterone every day, which often eventually stops periods altogether [7].
- LNG-IUD: A hormonal IUD can sometimes provide both contraception and local endometrial protection.
Duration of Treatment
The general medical consensus is that you should continue HRT until at least the average age of natural menopause, which is approximately 50 to 51 years old [14][15]. At that point, you and your doctor can discuss whether to taper off the hormones or continue them based on your symptoms and health goals.
Safety and Contraindications
For most women with FXPOI, the benefits of HRT help mitigate symptoms and health risks. However, management must be individualized, and specialist review is needed for certain conditions:
- Estrogen-Sensitive Cancers: Active or prior breast or endometrial cancer requires specialized consideration [16][17].
- Blood Clots (VTE) or Arterial Disease: If you have a history of blood clots, thrombophilia, or stroke, your management must be individualized. Transdermal estrogen is not automatically safe for someone with a prior clot; this requires specialist review [8][18].
- Unexplained Vaginal Bleeding: Any unusual bleeding must be investigated before starting or adjusting hormones [16].
- Active Liver Disease.
A Note on Contraception
It is a common misconception that HRT acts as birth control. While FXPOI means ovulation is rare and unpredictable, spontaneous pregnancies do happen [15]. If you do not wish to become pregnant, you may need to use a separate form of contraception. Combined Hormonal Contraceptives (like the pill or ring) are an alternative option for some patients, but they are not automatically interchangeable with POI HRT and should not be combined with systemic HRT without clinician direction [2][19].
Common questions in this guide
Why is HRT recommended when I have FXPOI?
What estrogen dose is usually used for FXPOI?
Is an estrogen patch safer than an estrogen pill?
Why do I need progestogen with estrogen if I still have my uterus?
How long should I take HRT for FXPOI?
Can HRT prevent pregnancy?
What health conditions need special review before starting HRT?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Estrogen delivery options
Would a patch or gel, or a daily pill, be more suitable for me?
Treatment duration
How long would hormone replacement therapy continue, and would my doctor help plan that?
Progestogen and uterus
If I still have my uterus, would I need a progestogen alongside estrogen?
Get notified when new evidence is published on Fragile X-associated primary ovarian insufficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Management of menopause.
Magraith K, Jang C
Australian prescriber 2023; (46(3)):48-53 doi:10.18773/austprescr.2023.014.
PMID: 38053812 - 2
HRT for women with premature ovarian insufficiency: a comprehensive review.
Webber L, Anderson RA, Davies M, et al.
Human reproduction open 2017; (2017(2)):hox007 doi:10.1093/hropen/hox007.
PMID: 30895225 - 3
Hormone therapy regimens for managing the menopause and premature ovarian insufficiency.
Armeni E, Paschou SA, Goulis DG, Lambrinoudaki I
Best practice & research. Clinical endocrinology & metabolism 2021; (35(6)):101561 doi:10.1016/j.beem.2021.101561.
PMID: 34274232 - 4
Long-term health consequences of premature or early menopause and considerations for management.
Faubion SS, Kuhle CL, Shuster LT, Rocca WA
Climacteric : the journal of the International Menopause Society 2015; (18(4)):483-91 doi:10.3109/13697137.2015.1020484.
PMID: 25845383 - 5
Improving Treatment of Radiation-Induced Premature Ovarian Insufficiency After Cervical Cancer: A Practice Quality Improvement Initiative.
Smith EE, Heintz JR, Chesnokova A, Taunk NK
International journal of radiation oncology, biology, physics 2026; (126(1)):48-54 doi:10.1016/j.ijrobp.2026.02.211.
PMID: 41698471 - 6
Expert opinion by the Italian Society of Gynecology of the Third Age (SIGiTE) and the Italian Society of Menopause (SIM) on diagnosis and treatment of premature ovarian insufficiency.
Capozzi A, Ambroggio S, Cagnacci A, et al.
Minerva endocrinology 2026; (51(1)):88-95 doi:10.23736/S2724-6507.25.04422-7.
PMID: 41212137 - 7
Premature ovarian insufficiency: Updated concepts in diagnosis and hormonal treatment strategies.
Pravatta-Rezende G, Benetti-Pinto CL, Yela DA, et al.
Clinics (Sao Paulo, Brazil) 2025; (80()):100745 doi:10.1016/j.clinsp.2025.100745.
PMID: 40840112 - 8
Menopause-associated risk of cardiovascular disease.
Anagnostis P, Lambrinoudaki I, Stevenson JC, Goulis DG
Endocrine connections 2022; (11(4)).
PMID: 35258483 - 9
Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Anagnostis P, Paschou SA, Katsiki N, et al.
Current vascular pharmacology 2019; (17(6)):564-572 doi:10.2174/1570161116666180709095348.
PMID: 29984659 - 10
Hormone replacement therapy in gynecologic cancer survivors: bridging the gap between evidence and clinical practice.
Gil-Ibáñez B, Luzarraga Aznar A, Barretina-Ginesta MP, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2026; 104881 doi:10.1016/j.ijgc.2026.104881.
PMID: 42660774 - 11
Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis.
Gonçalves CR, Vasconcellos AS, Rodrigues TR, et al.
Reproductive biomedicine online 2022; (44(6)):1143-1157 doi:10.1016/j.rbmo.2022.02.006.
PMID: 35461762 - 12
Isolated β-Human Chorionic Gonadotropin Elevation-From Pregnancy to Fragile X-associated Premature Ovarian Insufficiency.
Sharma PP
AACE endocrinology and diabetes 2026; (13(2)):308-312 doi:10.1016/j.aed.2025.11.008.
PMID: 41938280 - 13
Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency.
Craciunas L, Zdoukopoulos N, Vinayagam S, Mohiyiddeen L
The Cochrane database of systematic reviews 2022; (10()):CD008209 doi:10.1002/14651858.CD008209.pub2.
PMID: 36200708 - 14
Primary ovarian insufficiency: a toolkit for the busy clinician.
Kapoor E
Menopause (New York, N.Y.) 2024; (31(1)):65-67 doi:10.1097/GME.0000000000002275.
PMID: 38086010 - 15
Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency.
Obstetrics and gynecology 2017; (129(5)):e134-e141 doi:10.1097/AOG.0000000000002044.
PMID: 28426619 - 16
Premature ovarian insufficiency: When ovaries retire early.
Sugianto SRS, Webber L, Safdar Husain F, et al.
Annals of the Academy of Medicine, Singapore 2025; (54(3)):178-191 doi:10.47102/annals-acadmedsg.2024227.
PMID: 40178424 - 17
Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy.
Harris BS, Bishop KC, Kuller JA, et al.
Menopause (New York, N.Y.) 2020; (27(2)):243-248 doi:10.1097/GME.0000000000001447.
PMID: 31738735 - 18
[Menopause and risk of thromboembolic events. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].
Hugon-Rodin J, Perol S, Plu-Bureau G
Gynecologie, obstetrique, fertilite & senologie 2021; (49(5)):455-461 doi:10.1016/j.gofs.2021.03.018.
PMID: 33757918 - 19
Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome).
Christin-Maitre S, Givony M, Albarel F, et al.
Annales d'endocrinologie 2021; (82(6)):555-571 doi:10.1016/j.ando.2021.09.001.
PMID: 34508691
This page provides educational information about hormone replacement therapy for FXPOI and is not medical advice. Your clinician should tailor the estrogen dose, progestogen plan, and contraception to your health history.